Amanta Healthcare Ltd

Amanta Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcare Ltd has demonstrated a notable turnaround in its financial performance for the quarter ended December 2025, shifting from a flat to a positive growth trajectory. This improvement is reflected in key metrics such as revenue, profitability, and operating efficiency, signalling a potential stabilisation in the company’s business fundamentals despite broader market headwinds.

Amanta Healthcare Ltd. reported a robust 282.64% quarter-on-quarter surge in net profit for Q3 FY26, reaching ₹4.63 crores compared to ₹1.21 crores in Q2 FY26, whilst also posting a modest 8.15% year-on-year growth from ₹4.28 crores in Q3 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹413 crores, saw its stock trade at ₹107.75 on February 10, 2026, up 1.51% from the previous close. However, beneath the headline profit growth lies a complex narrative of margin compression and operational challenges that warrant closer scrutiny from investors.

Amanta Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 03 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcar is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcar is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcar is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 December 2025, providing investors with the latest insights into the company’s performance and outlook.

Amanta Healthcare’s recent market assessment reflects a nuanced picture shaped by its financial performance, valuation metrics, and technical indicators. The pharmaceutical company’s long-term sales trajectory, debt servicing capacity, and return ratios have influenced a revision in its evaluation, highlighting both challenges and areas of relative strength within a competitive sector.

Amanta Healthcare, a player in the Pharmaceuticals & Biotechnology sector, has experienced a shift in its business fundamentals as reflected in recent evaluation adjustments. Key financial metrics such as return on equity, return on capital employed, debt levels, and growth indicators reveal a nuanced picture of the company’s operational and financial health amid a challenging market environment.